Atrial Septal Defect Closure Device & Ventricular Septal Defect Closure Device Market Size, Share & Trends Analysis | Global | 2025-2032

Global Atrial and Ventricular Septal Defect Closure Device Market Report to 2032

The global atrial and ventricular septal defect closure device market was valued at $190.9 million in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 1.8%, reaching $215.7 million by 2032.

This report covers the global market for atrial and ventricular septal defect closure devices, including products used to treat atrial septal defects and ventricular septal defects through percutaneous closure.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market growth is supported by iatrogenic ASD cases, demographic factors, improved detection of congenital heart defects, and expanded access to echocardiography. However, limited patient population size and market saturation are expected to constrain stronger growth.

Market Overview

The global atrial and ventricular septal defect closure device market includes devices used to close openings in the septum between the heart's chambers. These devices are placed percutaneously through the defect, where they expand and form a seal.

Many of these devices are designed to allow heart tissue to grow over the device over time. This supports long-term closure while avoiding the need for open surgical repair in appropriately selected patients.

Market demand is supported by sustained prevalence and improved detection of atrial septal defects. Expanded access to echocardiography and routine cardiovascular screening has led to earlier diagnosis and increased identification of congenital heart defects.

As a result, procedural volumes for ASD closure are expected to increase modestly. This contributes to stable growth in the septal defect closure device market, although the overall market remains limited by a narrow treatable patient pool and mature adoption in developed regions.

Market Drivers

Iatrogenic ASD

The prevalence of iatrogenic atrial septal defects has increased dramatically in recent years. This growth is linked to the rising number of left atrial transcatheter procedures performed through a transeptal approach.

Examples include MitraClip procedures, left atrial appendage closure, cardiac ablation, and other left-sided interventions. These procedures can create atrial septal defects as part of the access pathway.

Based on current clinical guidelines, only a small percentage of iatrogenic ASDs require immediate closure. Closure is usually considered when the patient cannot tolerate shunting at the atrial level. Until guidelines more strongly reinforce closure of iatrogenic ASD, this will remain a relatively small segment of the total ASD market.

However, transcatheter mitral valve repair and LAA closure are relatively high-volume procedures. Even a small percentage of iatrogenic ASD cases requiring immediate closure could drive modest growth in the mature ASD market.

Demographic Factors

Demographic factors also support growth in the atrial and ventricular septal defect closure device market. As the global population increases, the number of patients requiring ASD or VSD closure is expected to rise.

Although ASD and VSD treatment remains a specialized congenital and structural heart market, a larger population base increases the number of potential diagnoses over time.

In addition, improved access to advanced healthcare in developing economies is driving growth in key international markets. As more patients gain access to diagnostic imaging and interventional cardiology services, more treatable defects may be identified and addressed.

Improved Detection and Screening

Improved detection of congenital heart defects is supporting market demand. Expanded access to echocardiography and routine cardiovascular screening has increased the identification of atrial septal defects.

Earlier diagnosis can help physicians determine whether a defect requires monitoring, percutaneous closure, or surgical repair. Better screening also allows patients to enter the treatment pathway before complications become more severe.

This trend is especially important in emerging markets, where improved healthcare access can raise diagnosis rates from historically lower levels. As diagnostic pathways strengthen globally, procedural volumes are expected to increase modestly.

Market Limiters

Limited Patient Population

The main limiter of the atrial and ventricular septal defect closure device market is the limited patient population. Many people with ASDs or VSDs never show symptoms and do not require treatment.

This limits the number of devices that can be sold. Even when a defect is diagnosed, closure is not always necessary, and patients may be monitored rather than treated.

Many ASD patients are also not suitable for percutaneous closure. Patients with primum, sinus venosus, or coronary sinus type defects, severe pulmonary hypertension, Eisenmenger syndrome, net right-to-left shunt, defects larger than 38 mm, or insufficient rim tissue around the defect may require open surgery instead.

Until more ASDs and VSDs are diagnosed and treated through percutaneous methods, the market will remain constrained by patient eligibility.

Market Saturation

The atrial and ventricular septal defect closure device market has become increasingly saturated. In most developed regions, procedural volumes have stabilized, and the addressable patient population is well defined.

Because the patient pool is limited, there are few opportunities for significant unit growth in mature markets. Most growth is expected to come from improved diagnosis, emerging market access, and selected new indications such as iatrogenic ASD closure.

Market maturity has also intensified competition among manufacturers. With limited room for major procedural expansion, companies must compete on pricing, product familiarity, distribution, and physician preference.

Pricing Pressure and Limited Differentiation

Pricing pressure is another important limiter in this mature market. As competition increases and procedural volumes stabilize, manufacturers face pressure to maintain affordability.

Device differentiation can also be limited, especially in markets where physicians are already familiar with established occluder platforms. When products are viewed as similar in function, purchasing decisions may become more price-sensitive.

This environment is expected to restrain overall market value growth over the forecast period. Even if unit demand rises modestly, ASP pressure may limit the revenue benefit for suppliers.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.
• Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, and forecast assumptions.
• Device scope: The report covers devices used to treat atrial and ventricular septal defects percutaneously by inserting a device through the defect, where it expands and forms a seal around the opening.

Markets Covered and Segmentation

Atrial and Ventricular Septal Defect Closure Device Market

• Device type: Atrial septal defect closure devices and ventricular septal defect closure devices.

Atrial septal defect closure devices are used to close openings between the atrial chambers of the heart. These devices are most often used when the defect is suitable for percutaneous closure and the patient does not require open surgery.

Ventricular septal defect closure devices are used to close openings between the ventricular chambers of the heart. These procedures are more selective and depend on defect type, location, size, patient anatomy, and clinical need.

Many septal defect closure devices are designed so that tissue can grow over the device with time, supporting long-term sealing of the defect.

Each segment is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.

This segmentation helps manufacturers, investors, and strategy teams understand how ASD and VSD closure demand is shaped by diagnosis rates, patient eligibility, percutaneous suitability, surgical alternatives, pricing pressure, and regional access.

Competitive Analysis

Abbott was the leading competitor in the global ASD and VSD closure device market in 2025. The company offers the Amplatzer(TM) line, which includes both atrial septal defect and ventricular septal defect closure devices.

Abbott benefits from its early market presence, physician familiarity, and broad global availability. Because there are a limited number of companies with a true global presence in this market, Abbott is expected to maintain its share over the coming years.

The Amplatzer(TM) platform remains a key product line in septal defect closure. Its established use supports Abbott's leadership in a market where physician confidence and long-term product familiarity are important.

Gore was the second-leading competitor in the global ASD and VSD closure device market in 2025. The company offers the Gore(R) Cardioform Septal Occluder.

Gore participates mainly in the atrial closure market regionally. Although the Cardioform Septal Occluder supports the company's position in structural heart closure, smaller local companies may limit Gore's expansion in some markets.

The competitive landscape remains shaped by established occluder platforms, regional product availability, and local supplier competition. As the market matures, companies with strong distribution, proven device performance, and physician training support are expected to remain best positioned.

Technology and Practice Trends

Percutaneous Closure

Percutaneous closure remains the central technology and practice trend in this market. Devices are inserted through the defect and expand to create a seal, reducing the need for open surgery in suitable patients.

This approach supports shorter recovery and lower procedural burden compared with surgical repair.

Tissue Overgrowth and Long-Term Sealing

Many closure devices are designed to allow heart tissue to grow over the device over time. This helps create a long-term seal around the defect.

This feature supports device stability and long-term procedural success.

ASD Detection Through Echocardiography

Expanded access to echocardiography is improving detection of atrial septal defects. Earlier and more accurate diagnosis can increase the number of patients evaluated for treatment.

This is expected to support modest procedural volume growth.

Iatrogenic ASD Closure

Iatrogenic ASD is becoming more relevant as left atrial transcatheter procedures increase. Mitral repair, LAA closure, and ablation procedures performed through transeptal access can create defects that may occasionally require closure.

This remains a small but potentially growing use case.

Surgical Versus Percutaneous Selection

Not all ASDs or VSDs are suitable for percutaneous closure. Some patients require open surgery because of defect type, size, anatomy, or associated conditions.

Patient selection will remain central to market demand.

Mature Market Competition

In developed regions, the market is mature and highly competitive. Pricing pressure, limited differentiation, and local competition are expected to shape supplier performance.

Manufacturers will need to rely on clinical familiarity, device reliability, and regional access to maintain share.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• How large is the global atrial and ventricular septal defect closure device market today, and how much is it expected to grow through 2032?
• How are unit sales, procedure numbers, ASPs, and market values changing over time?
• What role do ASD and VSD closure devices play in congenital and structural heart treatment?
• How is improved echocardiography access affecting diagnosis rates?
• How are iatrogenic ASDs creating new demand after left atrial transcatheter procedures?
• Why does the limited patient population constrain total market potential?
• Which patients are suitable for percutaneous closure versus open surgery?
• How is market saturation affecting pricing and competition?
• Which companies lead the global ASD and VSD closure device market?
• How are Abbott and Gore positioned in the competitive landscape?

The Global Atrial and Ventricular Septal Defect Closure Device Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand septal closure trends, and support commercial planning in the global ASD and VSD closure device market.